Structural Heart Disease

Structural heart diseases include any issues preventing normal cardiovascular function due to damage or alteration to the anatomical components of the heart. This is caused by aging, advanced atherosclerosis, calcification, tissue degeneration, congenital heart defects and heart failure. The most commonly treated areas are the heart valves, in particular the mitral and aortic valves. These can be replaced through open heart surgery or using cath lab-based transcatheter valves or repairs to eliminate regurgitation due to faulty valve leaflets. This includes transcatheter aortic valve replacement (TAVR). Other common procedures include left atrial appendage (LAA) occlusion and closing congenital holes in the heart, such as PFO and ASD. A growing area includes transcatheter mitral repair or replacement and transcatheter tricuspid valve repair and replacement.

RSS icon

Haines takes helm at Saint Luke’s CV ICU

Saint Luke’s Mid America Heart Institute in Kansas City, Mo., has named Michelle M. Haines, MD, medical director of its cardiovascular intensive care unit (ICU).

ACC.13: Heart-pounding late-breakers

What a wild ride it has been, and most of us have not even packed our bags yet. I am talking about the late-breaking clinical trials program at the American College of Cardiology scientific sessions in San Francisco, which will kick off March 9.

FDA gives thumbs up to Philips EchoNavigator

Philips has received 510(k) clearance from the FDA to market its EchoNavigator live image-guidance tool. 

FDA once again jilts Xarelto

The FDA has issued a second complete response letter on a supplemental New Drug Application for rivaroxaban for the reduction of the risk of cardiovascular events in patients with acute coronary syndrome.

25% choose not to THRIVE on niacin therapy

One-quarter of patients with occlusive arterial disease who received extended release niacin in addition to statins discontinued treatment, primarily due to adverse reactions. Results, published online Feb. 27 in European Heart Journal , showed a four-fold excess risk of myopathy in patients taking the combination therapy, with patients in China facing even higher risks.

Benefits of a wealth of data

What do you do when the cat is let out of the bag, and has been for several months? That is the quandary facing the American College of Cardiology (ACC) with one of its late-breaking clinical trials.

Medtronic's Engager TAVI gets EU stamp of approval

Medtronic has received CE Mark for its Engager transcatheter aortic valve implantation (TAVI) system with transapical delivery catheter to treat patients with severe aortic stenosis who are at high or extreme risk for surgical aortic valve replacement.

EMA cites heart issues in Qsiva’s rejection

The European Medicines Agency (EMA) once again gave a cold shoulder to Qsiva as a treatment for severely obese or obese patients, citing concerns about long-term cardiovascular effects.

Displaying 1561 - 1568 of 2350

Around the web

Radiology Business
Key takeaways from RSNA 2024 for AI, CT, MRI and the radiology staffing shortage

Several key trends were evident at the Radiological Society of North America 2024 meeting, including new CT and MR technology and evolving adoption of artificial intelligence.

Health Imaging
Use of AI opportunistic screening in CT for cardiovascular disease

Ron Blankstein, MD, professor of radiology, Harvard Medical School, explains the use of artificial intelligence to detect heart disease in non-cardiac CT exams.